Changmok Oh

Title: Changmok Oh: Innovator in Pharmaceutical Development

Introduction

Changmok Oh is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target metabolic diseases and related disorders. With a total of three patents to his name, his work showcases innovative approaches to addressing critical health issues.

Latest Patents

Changmok Oh's latest patents include a GLP-1 receptor agonist and its applications. This patent discloses novel compounds that exhibit excellent activity as GLP-1 receptor agonists, demonstrating significant potential for therapeutic use in metabolic diseases. The compounds show remarkable glucose tolerance and pharmacological safety for cardiovascular systems. Another notable patent involves substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators. This patent provides compounds that can modulate CFTR functionality and offers methods for treating eye diseases and inflammatory disorders.

Career Highlights

Changmok Oh is currently associated with Il Dong Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing therapeutic options for various health conditions, particularly those related to metabolic and inflammatory diseases.

Collaborations

Some of his notable coworkers include Kyung Mi An and Jin Hee Lee, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Changmok Oh's contributions to pharmaceutical innovations highlight his role as a key inventor in the industry. His patents reflect a commitment to improving health outcomes through scientific advancements.